Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease ; volume:79 ; number:5 ; day:15 ; month:3 ; year:2019 ; pages:555-562 ; date:4.2019
Drugs ; 79, Heft 5 (15.3.2019), 555-562, 4.2019
- Creator
-
Shirley, Matt
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-019-01095-z
- URN
-
urn:nbn:de:101:1-2019042720452055530546
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shirley, Matt
- SpringerLink (Online service)
Other Objects (12)
Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
A comparative study of Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuisin experimentally infected pigs
Genomic homogeneity between Mycobacterium avium subsp. avium and Mycobacterium avium subsp. paratuberculosis belies their divergent growth rates
Efflux-Inhibition bei Mycobacterium smegmatis und Mycobacterium avium
Entwicklung einer Realtime-PCR zum Nachweis von Mycobacterium avium ssp. avium und Mycobacterium avium ssp. silvaticum beim Vogel
Entwicklung einer Realtime-PCR zum Nachweis von Mycobacterium avium ssp. avium und Mycobacterium avium ssp. silvaticum beim Vogel
Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
A comparative study of Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuisin experimentally infected pigs
Genomic homogeneity between Mycobacterium avium subsp. avium and Mycobacterium avium subsp. paratuberculosis belies their divergent growth rates
Efflux-Inhibition bei Mycobacterium smegmatis und Mycobacterium avium
Entwicklung einer Realtime-PCR zum Nachweis von Mycobacterium avium ssp. avium und Mycobacterium avium ssp. silvaticum beim Vogel
Entwicklung einer Realtime-PCR zum Nachweis von Mycobacterium avium ssp. avium und Mycobacterium avium ssp. silvaticum beim Vogel
Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
A comparative study of Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuisin experimentally infected pigs
Genomic homogeneity between Mycobacterium avium subsp. avium and Mycobacterium avium subsp. paratuberculosis belies their divergent growth rates
Efflux-Inhibition bei Mycobacterium smegmatis und Mycobacterium avium
Entwicklung einer Realtime-PCR zum Nachweis von Mycobacterium avium ssp. avium und Mycobacterium avium ssp. silvaticum beim Vogel